Scarica l'app Stockscreener
6.00
1.18%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.93
Aprire:
$5.89
Volume 24 ore:
866.46K
Relative Volume:
0.64
Capitalizzazione di mercato:
$343.10M
Reddito:
$5.82M
Utile/perdita netta:
$71.18M
Rapporto P/E:
6.0168
EPS:
0.9972
Flusso di cassa netto:
$-84.30M
1 W Prestazione:
+1.35%
1M Prestazione:
-12.02%
6M Prestazione:
+20.72%
1 anno Prestazione:
-12.54%
Intervallo 1D:
$5.85
$6.02
Intervallo di 1 settimana:
$5.78
$6.10
Portata 52W:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Nome
Abeona Therapeutics Inc
Settore
Industria
Telefono
646-813-4701
Indirizzo
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.00 | 340.82M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-03-05 | Iniziato | Oppenheimer | Outperform |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Stifel | Buy |
| 2020-11-11 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-02-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-10 | Ripresa | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Downgrade | Maxim Group | Buy → Hold |
| 2019-08-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Downgrade | Mizuho | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2018-10-12 | Iniziato | Mizuho | Buy |
| 2018-06-05 | Iniziato | Seaport Global Securities | Buy |
| 2017-11-08 | Iniziato | SunTrust | Buy |
| 2017-10-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Iniziato | Citigroup | Buy |
| 2017-10-05 | Reiterato | Maxim Group | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-18 | Reiterato | Maxim Group | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-01-06 | Iniziato | Jefferies | Buy |
| 2016-09-29 | Reiterato | Maxim Group | Buy |
Mostra tutto
Abeona Therapeutics Inc Borsa (ABEO) Ultime notizie
High Insider Ownership Growth Stocks To Watch In August 2026 - simplywall.st
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone - Yahoo Finance
Abeona (ABEO) Latest Quarter: EPS Misses Its Estimate in the Latest Session; Market Reaction: The Market Price Declines 2.77% for the Current SessionRevenue Growth Outlook - vinanet.vn
Abeona (ABEO) Q2 2026 Earnings Call Transcript - AOL.com
ABEO: Zevaskyn Launch Gains Momentum - Smartkarma
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlight - GuruFocus
Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty - GuruFocus
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ... - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Understanding the Setup: (ABEO) and Scalable Risk - Stock Traders Daily
Abeona Therapeutics Insiders Sell US$2.9m Of Stock, Possibly Signalling Caution - Moomoo
Abeona Therapeutics Stock Price Forecast. Should You Buy ABEO? - StockInvest.us
Montanova Capital (ABEO) reports 0.9% beneficial stake in Abeona Therapeutics - Stock Titan
ABEO Maintained by Oppenheimer -- Price Target Lowered to $21.00 - GuruFocus
Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating - marketscreener.com
Abeona Therapeutics (ABEO) Q2 2026 Earnings Call: ZEVASKYN Revenue Rises 31% - TradingKey
Abeona Therapeutics (ABEO) Stock Faces Early Launch Strain Despite Revenue Traction - Sahm
Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Abeona Therapeutics Shares Fall After Q2 Miss - marketscreener.com
Abeona Therapeutics (ABEO) Advances ZEVASKYN Rollout Amid Mixed Valuation Signals - GuruFocus
Transcript : Abeona Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Abeona Therapeutics Q2 Results: Revenue Rises 31% QoQ To $11.4 Million - scanx.trade
Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa - GuruFocus
Abeona Therapeutics Down Nearly 15%, On Pace For Largest Percent Decrease Since April 2024 -- Data Talk - Moomoo
Abeona Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Abeona Therapeutics Q2 Earnings Call Highlights - MarketBeat
Abeona stock drops after Q2 revenue miss (ABEO:NASDAQ) - Seeking Alpha
Earnings call transcript: Abeona Therapeutics misses Q2 2026 revenue view as shares fall - Investing.com
Abeona Therapeutics Reports Q2 2026 Results in Form 10-Q Filing - Kalkine Media
Abeona Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why is Abeona Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Q2 Earnings Highlight Challenges Amid Soaring Price-to-Sales Ratio - GuruFocus
Is Abeona Therapeutics Inc (ABEO) Facing Sustainability Challeng - GuruFocus
Abeona Therapeutics: Q2 Earnings Snapshot - AOL.com
ABEONA THERAPEUTICS INC. Q2 2026: Revenue $11.38M, EPS $(0.35) — 10-Q Summary - TradingView
Abeona Therapeutics Q2 net loss widens, misses analyst expectations - TradingView
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Abeona Q2 Revenue Rises 31% to $11.4 Million - Quiver Quantitative
Abeona Therapeutics reports Q2 2026: $11.4M product revenue, $20.2M net loss - TradingView
Abeona Therapeutics (ABEO) grows ZEVASKYN sales but records H1 2026 net loss - Stock Titan
Abeona Q2 FY26 net loss widens to $20.2 million; revenue rises 31% Q/Q to $11.4 million - Bitget
Abeona Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Weekly Recap: CMS NTAP for ZEVASKYN and Q2 2026 results call - TradingView
Abeona will stream its Q2 financial update on Aug. 13 - Stock Titan
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - GlobeNewswire
Abeona Therapeutics (ABEO) Projected to Announce Earnings on Thursday - MarketBeat
The Technical Signals Behind (ABEO) That Institutions Follow - Stock Traders Daily
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics Inc Azioni (ABEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):